The Strategic Plan: An Interview with NHGRI Director Eric Green

In January, we reported on the National Human Genome Research Institute (NHGRI) Vision to Move Genomic Medicine from Base Pairs to Bedside. Written by Eric D. Green, M.D., Ph.D., Director of the NHGRI, Mark Guyer, Ph.D., Director of the Division of Extramural Research and Acting Deputy Director of the NHGRI, and others at the NHGRI, the plan maps the next steps the field of genomic research must take to discover medical secrets hidden within the human genome and transfer them to physicians and patients [1].

Interestingly, the strategic plan really isn’t a strategic plan but a list of issues to be addressed. And on this note, Daniel MacArthur, a genomics researcher and author of Wired’s Genetic Future, found the NHGRI document frustrating to read [2]:

… this is an impressive, worthwhile and highly readable piece of work, but one that ultimately feels unfinished. As research dollars begin to get tighter, there is an urgent need for an actual strategic plan for building the resources and tools required to make genomic medicine a reality within a realistic budget.

In other words: a specific NHGRI funding plan to overcome the issues. This could prove difficult in the current U.S. fiscal environment. Even though President Obama has resisted cuts to biomedical research funding in his 2012 budget proposal, the outlook isn’t bright. Decreasing NIH funding for short-range budget goals will disrupt five-year-long longitudinal studies make it impossible to start new research [3]. Moreover, it will hurt U.S. standing as the world leader in biomedical advances.

Genetic Signatures that Distinguish Cancer and Non-cancer Patients

A group of researchers led by scientists from the Virginia Bioinformatics Institute (VBI) at Virginia Tech have developed a new technology that detects distinct genetic changes differentiating cancer patients from healthy individuals [1]. The technology is described in a recent study published in the journal Genes, Chromosomes and Cancer and may one day serve as the basis for a cancer predisposition test.

Biomarker Bulletin: March 21, 2011

Biomarker Bulletin is an occasionally recurring update of news focused on biomarkers aggregated at BiomarkerCommons.org. Biomarkers are physical, functional or biochemical indicators of normal physiological or disease processes. The individualization of disease management — personalized medicine — is dependent on developing biomarkers that promote specific clinical domains, including early detection, risk, diagnosis, prognosis and predicted response to therapy.

Biomarker Commons
  • MedTrust Online, Avantra Biosciences Collaborate to Involve Clinicians in Assay Development

    MedTrust Online and Avantra Biosciences recently announced that they will collaborate on involving clinicians in early-stage development of molecular diagnostic assays to run on Avantra Biosciences’ QPDx multiplex immunoassay system.

  • Biomarker May Prove Useful for Diagnosing Knee Injury

    Researchers from Stanford University School of Medicine recently discovered a biomarker that may enable doctors to diagnose a common form of knee injury. The study, published in the Journal of Bone and Joint Surgery, has identified a specific protein complex in the knee fluid of patients with painful meniscal tears.

  • OncoTrack Launches Search for Novel Genomic Cancer Diagnostics

    A new European consortium called OncoTrack has just launched one of Europe’s largest collaborative academic-industry research projects to develop and assess novel approaches for the identification of new biomarkers for colon cancer. The five year project, Methods for systematic next generation oncology biomarker development, brings together top European academic researchers with a wide range of expertise and partners them with pharmaceutical companies.

  • Discovery of Diagnostic and Prognostic Prostate Cancer Serum Biomarkers Guided by Cancer Genetics

    An interdisciplinary team of researchers from ETH Zurich, University Hospital Zurich and the Cantonal Hospital of St. Gallenhas has defined biomarkers in patients’ blood serum that indicates the presence of prostate cancer. The method used has the potential to be applied to other types of tumors.

  • SciClips Launches Diagnostic and Prognostic Biomarker Database

    In the era of personalized medicine, drugs will be targeted to patients based upon his or her unique genetic profile. Biomarkers are a critical component for tailoring treatments to individual patients. Biomarkers will be used as tools for target discovery, noninvasive early stage diagnosis of diseases, for evaluation of mode of action of a drug, dose determination and prediction of the drug effect. They will accelerate not only the development of effective and non-toxic drugs but also help in monitoring patient health and response to treatment.

Brain Awareness Week: Staying Sharp

As Brain Awareness Week comes to a close here at Highlight HEALTH, we wanted to leave you with a video from the Dana Foundation that addresses the science behind the healthy brain practices that may help us stay sharp as we get older — the lifestyle factors that may contribute to the maintenance of cognitive function.

Don’t forget that we’re giving away several publications for Brain Awareness Week; in particular, the bookmark was created to be paired with the Staying Staying Sharp booklet (link below) and video (below).

Brain Awareness Week

Dr. Jordan Grafman, chief of the Cognitive Neuroscience Section at the National Institute of Neurological Disorders and Stroke (NINDS), and a member of the Dana Alliance for Brain Initiatives, is your guide as we cover what to expect from the aging brain and what you can do to “stay sharp”.

Building a Circuit Diagram of the Brain

Jennifer Raymond, an associate professor in neurobiology at Stanford University, is building a circuit diagram of the brain. By bridging the gap between individual synapses and whole brain learning and memory, her research is offering new insights and strategies for medical rehabilitation and education.